# AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

Study · id `cardio:ct-nct03317002` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03317002](<https://clinicaltrials.gov/study/NCT03317002>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03317002

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT03317002. Randomized; triple masking; primary purpose treatment. Start 2017-10-30 (actual); primary completion 2020-04-08 (actual). Results posted on 2021-06-30.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT03317002, source copy `cardio:ctgov-nct03317002-2021-06-30`, retrieved 2026-10-26)
- Started: 2017-10-30 (actual) (ClinicalTrials.gov record NCT03317002, source copy `cardio:ctgov-nct03317002-2021-06-30`, retrieved 2026-10-26)
- Primary completion: 2020-04-08 (actual) (ClinicalTrials.gov record NCT03317002, source copy `cardio:ctgov-nct03317002-2021-06-30`, retrieved 2026-10-26)
- Completion: 2020-04-08 (actual) (ClinicalTrials.gov record NCT03317002, source copy `cardio:ctgov-nct03317002-2021-06-30`, retrieved 2026-10-26)
- Results first posted: 2021-06-30 (ClinicalTrials.gov record NCT03317002, source copy `cardio:ctgov-nct03317002-2021-06-30`, retrieved 2026-10-26)
- Countries: Denmark; Finland; Sweden (ClinicalTrials.gov record NCT03317002, source copy `cardio:ctgov-nct03317002-2021-06-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03317002-2021-06-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
- Acronym: FLAVOUR
- Condition: Coronary Artery Disease
- Intervention (Drug): AZD5718
- Intervention (Drug): AZD5718
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study (`cardio:pubmed-35842004`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d21e14eedf3c7aecbd3379fc6b6b90261180aa557b54fe550b89fa37de6b54a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
